Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free MBX Stock Alerts

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.30 +0.01 (+1.72%)
As of 03:59 PM Eastern
Compare

MBX vs. IPA, AKU, GEN, LMD, and LXG

Should you buy Microbix Biosystems stock or one of its competitors? Microbix Biosystems's main competitors and comparable companies include ImmunoPrecise Antibodies (IPA), Akumin (AKU), GeneNews (GEN), LED Medical Diagnostics (LMD), and LexaGene (LXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Microbix Biosystems compare to ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (CVE:IPA) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

0.2% of Microbix Biosystems shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Microbix Biosystems had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Microbix Biosystems'average media sentiment score.

Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
Microbix Biosystems Neutral

Microbix Biosystems has lower revenue, but higher earnings than ImmunoPrecise Antibodies. Microbix Biosystems is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

ImmunoPrecise Antibodies has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. ImmunoPrecise Antibodies' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise AntibodiesN/A N/A N/A
Microbix Biosystems -31.72%-18.83%3.82%

Summary

Microbix Biosystems beats ImmunoPrecise Antibodies on 6 of the 11 factors compared between the two stocks.

How does Microbix Biosystems compare to Akumin?

Microbix Biosystems (TSE:MBX) and Akumin (TSE:AKU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Microbix Biosystems has a beta of 0.759386, meaning that its share price is 24% less volatile than the broader market. Comparatively, Akumin has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

0.2% of Microbix Biosystems shares are held by institutional investors. Comparatively, 30.3% of Akumin shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by insiders. Comparatively, 33.0% of Akumin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Microbix Biosystems has higher earnings, but lower revenue than Akumin. Microbix Biosystems is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A
AkuminC$737.69M0.00-C$255.80M-C$3.80N/A

Microbix Biosystems has a net margin of -31.72% compared to Akumin's net margin of -34.67%. Microbix Biosystems' return on equity of -18.83% beat Akumin's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-31.72% -18.83% 3.82%
Akumin -34.67%-483.86%0.47%

In the previous week, Microbix Biosystems had 1 more articles in the media than Akumin. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for Akumin. Microbix Biosystems' average media sentiment score of 0.00 equaled Akumin'saverage media sentiment score.

Company Overall Sentiment
Microbix Biosystems Neutral
Akumin Neutral

Summary

Microbix Biosystems beats Akumin on 7 of the 11 factors compared between the two stocks.

How does Microbix Biosystems compare to GeneNews?

GeneNews (TSE:GEN) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Microbix Biosystems has higher revenue and earnings than GeneNews. Microbix Biosystems is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234.59K0.00-C$11.56M-C$0.07N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Microbix Biosystems had 1 more articles in the media than GeneNews. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for GeneNews. GeneNews' average media sentiment score of 0.00 equaled Microbix Biosystems'average media sentiment score.

Company Overall Sentiment
GeneNews Neutral
Microbix Biosystems Neutral

GeneNews has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. GeneNews' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
GeneNewsN/A N/A N/A
Microbix Biosystems -31.72%-18.83%3.82%

Summary

Microbix Biosystems beats GeneNews on 7 of the 10 factors compared between the two stocks.

How does Microbix Biosystems compare to LED Medical Diagnostics?

LED Medical Diagnostics (CVE:LMD) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Microbix Biosystems had 1 more articles in the media than LED Medical Diagnostics. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for LED Medical Diagnostics. LED Medical Diagnostics' average media sentiment score of 0.00 equaled Microbix Biosystems'average media sentiment score.

Company Overall Sentiment
LED Medical Diagnostics Neutral
Microbix Biosystems Neutral

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Microbix Biosystems has higher revenue and earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96M1.04-C$1.51M-C$0.04N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

LED Medical Diagnostics has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. LED Medical Diagnostics' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
LED Medical DiagnosticsN/A N/A N/A
Microbix Biosystems -31.72%-18.83%3.82%

Summary

Microbix Biosystems beats LED Medical Diagnostics on 9 of the 11 factors compared between the two stocks.

How does Microbix Biosystems compare to LexaGene?

LexaGene (CVE:LXG) and Microbix Biosystems (TSE:MBX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

LexaGene has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market. Comparatively, Microbix Biosystems has a beta of 0.759386, meaning that its share price is 24% less volatile than the broader market.

Microbix Biosystems has higher revenue and earnings than LexaGene. Microbix Biosystems is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneC$110.93K133.13-C$8.54M-C$0.08N/A
Microbix BiosystemsC$15.40M2.62C$3.39M-C$0.04N/A

LexaGene has a net margin of 0.00% compared to Microbix Biosystems' net margin of -31.72%. Microbix Biosystems' return on equity of -18.83% beat LexaGene's return on equity.

Company Net Margins Return on Equity Return on Assets
LexaGeneN/A -339.54% -120.21%
Microbix Biosystems -31.72%-18.83%3.82%

0.1% of LexaGene shares are owned by institutional investors. Comparatively, 0.2% of Microbix Biosystems shares are owned by institutional investors. 17.9% of LexaGene shares are owned by insiders. Comparatively, 14.0% of Microbix Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Microbix Biosystems had 1 more articles in the media than LexaGene. MarketBeat recorded 1 mentions for Microbix Biosystems and 0 mentions for LexaGene. LexaGene's average media sentiment score of 0.00 equaled Microbix Biosystems'average media sentiment score.

Company Overall Sentiment
LexaGene Neutral
Microbix Biosystems Neutral

Summary

Microbix Biosystems beats LexaGene on 7 of the 12 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

Export
MetricMicrobix BiosystemsLife Sciences Tools & Services IndustryHealthcare SectorTSE Exchange
Market CapC$40.41MC$9.93BC$7.17BC$12.49B
Dividend Yield2.30%1.46%2.53%6.25%
P/E Ratio-8.1965.01272.9939.34
Price / Sales2.62111.65612.739.85
Price / Cash4.1326.8677.8282.29
Price / Book1.6435.9812.854.71
Net IncomeC$3.39MC$56.67BC$3.47BC$299.09M
7 Day Performance-7.81%-0.83%1.24%-0.25%
1 Month Performance1.72%4.54%5.81%3.15%
1 Year Performance31.11%26.48%25.75%28.90%

Microbix Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.30
+1.7%		N/A+18.4%C$40.41MC$15.40MN/AN/A
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/A+0.0%C$162.08MC$19.47MN/A80
AKU
Akumin
N/AN/AN/AN/AC$37.20MC$737.69MN/A1,527
GEN
GeneNews
N/AN/AN/AN/AC$25.49MC$234.59KN/A2,700
LMD
LED Medical Diagnostics
N/AC$0.40
+∞		N/A+0.0%C$15.51MC$14.96MN/A46

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MBX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Congress Just Opened the Floodgates
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel